Linked Life Data

17956517

Source:http://linkedlifedata.com/resource/pubmed/id/17956517

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-10-24
pubmed:abstractText
Very severe asthma and local pulmonary steroid resistance causes major problems for patients, physicians and the health system at large. It usually results in multiple admissions to hospital and high morbidity. Omalizumab was used to treat such patients with success. However, in doing so, it raised a number of issues relating to the best methods of using this treatment in such patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1323-7799
pubmed:author
pubmed:issnType
Print
pubmed:volume
12 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S29-34; discussion S45-7
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Omalizumab (Xolair) in patients with steroid-resistant asthma: lessons to be learnt.
pubmed:affiliation
Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Perth, Western Australia, Australia. pjthomps@liwa.uwa.edu.au
pubmed:publicationType
Journal Article, Case Reports